Russian Heart Failure Journal 2008year The use of levosimendan in a pregnant patient with dilated cardiomyopathy
2008/
The use of levosimendan in a pregnant patient with dilated cardiomyopathy
Fedorova M. V., Pichugin V. V., Tyurina T. A., Sokolov V. V., Shakhova E. B.
Keywords:
DOI:
1. Follath F, Cleland JG, Just H et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360 (9328):196–202.
2. Moiseyev VS, Põder P, Andrejevs N et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23 (18):1422–1432.
3. Figgitt D, Gillies P, Goa K. Levosimendan. Drugs. 2001;61 (5):613–627.
4. Cleland JG, McGowan J. Levosimendan: a new era for inodilator therapy for heart failure? Curr Opin Cardiol. 2002;17 (3):257–265.
5. Ukkonen H, Saraste M, Akkila J, Knuuiti J. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther. 2000;68 (5):522–531.
6. Kaheinen P, Pollesello P, Levijoki J, Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol. 2001;37 (4):367–374.
7. Bowman P, Haikala H, Paul RJ. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth musclethrough calcium desensitization. J Pharmacol Exp Ther. 1999;288 (1):316–325.
8. Labriola C, Siro-Brigiani M, Carrata F et al. Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery. Int J Clin Pharmacol Ther. 2004;42 (4):204–211.
2. Moiseyev VS, Põder P, Andrejevs N et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23 (18):1422–1432.
3. Figgitt D, Gillies P, Goa K. Levosimendan. Drugs. 2001;61 (5):613–627.
4. Cleland JG, McGowan J. Levosimendan: a new era for inodilator therapy for heart failure? Curr Opin Cardiol. 2002;17 (3):257–265.
5. Ukkonen H, Saraste M, Akkila J, Knuuiti J. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther. 2000;68 (5):522–531.
6. Kaheinen P, Pollesello P, Levijoki J, Haikala H. Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol. 2001;37 (4):367–374.
7. Bowman P, Haikala H, Paul RJ. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth musclethrough calcium desensitization. J Pharmacol Exp Ther. 1999;288 (1):316–325.
8. Labriola C, Siro-Brigiani M, Carrata F et al. Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery. Int J Clin Pharmacol Ther. 2004;42 (4):204–211.